3B Future Health Fund announces new investment in iOnctura
14 juil. 2020 03h00 HE
|
Helsinn Healthcare S.A.
3B Future Health Fund announces new investment in iOnctura MONACO, PRINCIPALITY OF MONACO, July 14, 2020: 3B Future Health Fund, previously known as Helsinn Investment Fund S.A., SICAR, today...
Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis
02 juil. 2020 07h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis Lugano, Switzerland and San Diego, USA, July 2, 2020 – Helsinn, a Swiss...
Helsinn Group supports Conquer Cancer, the ASCO Foundation’s COVID Impacts Cancer fund
10 juin 2020 08h30 HE
|
Helsinn Healthcare S.A.
Helsinn Group supports Conquer Cancer, the ASCO Foundation’s COVID Impacts Cancer fund Lugano, Switzerland, June 10, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer...
Helsinn announces launch of oral formulation of Akynzeo® in China
09 juin 2020 03h30 HE
|
Helsinn Healthcare S.A.
Helsinn announces launch of oral formulation of Akynzeo® in China Lugano, Switzerland, June 9, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease...
Helsinn announces FDA acceptance of IND application
08 juin 2020 08h30 HE
|
Helsinn Healthcare S.A.
Helsinn announces FDA acceptance of IND application for TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities Lugano, Switzerland, June 8, 2020: Helsinn, a Swiss...
Helsinn Group announces FDA approval of a new liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) injection in the United States
02 juin 2020 08h30 HE
|
Helsinn Healthcare S.A.
Helsinn Group announces FDA approval of a new liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) injection in the United States Lugano, Switzerland, June 2, 2020 – Helsinn, a Swiss...
Helsinn Therapeutics (U.S.), Inc. waives copay fees for cancer-treating drug VALCHLOR® (mechlorethamine) gel to ensure eligible patients have access to treatment during the COVID-19 crisis
20 avr. 2020 08h30 HE
|
Helsinn Healthcare S.A.
Helsinn Therapeutics (U.S.), Inc. waives copay fees for cancer-treating drug VALCHLOR® (mechlorethamine) gel to ensure eligible patients have access to treatment during the COVID-19 crisis Iselin,...
Helsinn announces European approval of the IV formulation of AKYNZEO® (fosnetupitant / palonosetron)
23 mars 2020 06h00 HE
|
Helsinn Healthcare S.A.
Helsinn announces European approval of the IV formulation of AKYNZEO® (fosnetupitant / palonosetron) Lugano, Switzerland, March 23, 2020 – Helsinn, the Swiss pharmaceutical group focused on building...
Helidon Xhixha and Giacomo “Jack” Braglia present the artwork The Twin Bottles: Message in a Bottle
10 mars 2020 07h15 HE
|
Helsinn Healthcare S.A.
Helidon Xhixha and Giacomo “Jack” Bragliapresent the artwork The Twin Bottles: Message in a BottleAn environmental message Principality of Monaco, Yacht Club de Monaco Marina The Twin Bottles:...
New Insights on Mechlorethamine/Chlormethine gel presented at 4th World Congress of Cutaneous Lymphomas
14 févr. 2020 08h00 HE
|
Helsinn Healthcare S.A.
New Insights on Mechlorethamine/Chlormethine gel presented at 4th World Congress of Cutaneous Lymphomas Lugano, Switzerland, February 14, 2020 – Helsinn, the Swiss pharmaceutical group focused on...